Aims/hypothesis Non-alcoholic fatty liver disease (NAFLD) is associated with insulin resistance and characterised by different degrees of hepatic lesion. Its pathogenesis and correlation with apoptosis and insulin resistance in insulin target tissues remains incompletely understood. We investigated how insulin signalling, caspase activation and apoptosis correlate with different NAFLD stages in liver, muscle and visceral adipose tissues. Methods Liver, muscle and adipose tissue biopsies from 26 morbidly obese patients undergoing bariatric surgery were grouped according to the Kleiner-Brunt scoring system into simple steatosis, and less severe and more severe nonalcoholic steatohepatitis (NASH). Apoptosis was assessed by DNA fragmentation, and caspase-2 and -3 activation. Insulin signalling and c-Jun NH 2 -terminal kinase (JNK) proteins were evaluated by western blot. Results Caspase-3 and -2 activation, and DNA fragmentation were markedly increased in the liver of patients with severe NASH vs in that of those with simple steatosis (p<0.01). Muscle tissue, and to a lesser extent the liver, had decreased tyrosine phosphorylated insulin receptor and insulin receptor substrate in patients with severe NASH, compared with those with simple steatosis (p < 0.01 muscle; p < 0.05 liver). Concomitantly, Akt phosphorylation decreased in muscle, liver and visceral adipose tissues in patients with severe NASH (at least p< 0.05). Finally, JNK phosphorylation was significantly increased in muscle (p< 0.01) and liver (p<0.05) from NASH patients, compared with tissue from those with simple steatosis. Conclusions/interpretation Our results demonstrate a link between apoptosis, insulin resistance and different NAFLD stages, where JNK and caspase-2 may play a key regulatory role.
Introduction
Non-alcoholic fatty liver disease (NAFLD) comprises a range of liver lesions from simple steatosis to inflammation, steatohepatitis and cirrhosis. While simple steatosis is usually benign, non-alcoholic steatohepatitis (NASH) is characterised by chronic hepatocyte injury as well as inflammation and/or fibrosis, which can lead to advanced fibrosis, cirrhosis, hepatocellular carcinoma and liverrelated death [1] . Increased fat accumulation appears to be the primary factor leading to insulin resistance, and imbalanced lipid synthesis and oxidation, culminating in hepatic steatosis. In addition, recent data suggest that mechanisms driving disease progression can also induce steatosis, which should therefore be considered part of the liver's early 'adaptive' response to stress [2] . Further stress signals, including oxidative stress and lipid peroxidation, lead to hepatocyte injury and inflammation, probably playing an important role in the transition from simple steatosis to NASH [3] . Interestingly, cell death by apoptosis may also constitute an important component of disease progression [4] . In fact, members of our team and others have already demonstrated that hepatocyte apoptosis is a prominent pathological feature in patients with NASH and NAFLD [5, 6] . Nevertheless, the exact mechanisms of hepatocyte apoptosis in NASH and underlying factors of NAFLD progression and pathogenesis remain incompletely understood.
Individuals with NAFLD typically display insulin resistance at the level of the muscle (reduced glucose uptake), liver (impaired suppression of hepatic glucose production) and adipose tissue (high lipolytic rates and increased circulating NEFA) [7] . In particular, by increasing visceral adiposity, obesity leads to increased plasma concentration of NEFA, thus being strongly associated with hepatic and muscular insulin resistance, and with fat deposition [8] . The pathways by which increased visceral adiposity leads to insulin resistance are not fully understood. Some authors suggest that lipolysis induced by TNF-α and IL-6, and resulting in inhibition of IRS and increased plasma NEFA, may represent a major mechanism [9, 10] . Still, the exact contribution of TNF-α in insulin resistance remains unclear, as other studies suggest that in vivo TNF-α neutralisation has no effects on insulin sensitivity [11] . Therefore, the absence of TNF-α might only partially protect against obesity-induced insulin resistance [12] .
In turn, it is well established that these and other proinflammatory cytokines are produced by M1 macrophages that have infiltrated the adipose tissue [13] . These findings were subsequently expanded to show that c-Jun NH 2 -terminal kinase (JNK) 1 activation in adipocytes is also responsible for inducing IL-6, either directly or by activating macrophages [14] . In fact, it is now generally established that JNK1 is central to obesity-induced insulin resistance, although JNK2 might also play a contributing role [15] .
Interestingly, JNK1 has opposite roles in the pathogenesis of hepatic steatosis that operate in a tissue-specific manner [16] . Studies in type 2 diabetes patients suggest that intramyocellular lipid accumulation and muscle insulin resistance precede the development of hepatic insulin resistance and type 2 diabetes [17] . Other studies have shown that hepatic steatosis may induce hepatic insulin resistance, or that the initial insulin resistance site is located in the periphery, probably in the skeletal muscle, followed by the liver, which further increases the degree of insulin resistance [18] .
The purpose of this study was to evaluate and identify: (1) particular mechanisms of liver cell apoptosis at different stages of NAFLD; and (2) how they might correlate with insulin signalling cascade activation. To do this, we used three major insulin target tissues, namely liver, muscle and adipose tissues. We also sought to investigate whether JNK activation might represent an additional mechanism linking apoptosis and insulin resistance at different NAFLD stages. Clinical data, laboratory assays and histology Evaluations were performed in the morning before the surgical procedure. Demographic data were obtained via structured interviews and questionnaires, evaluating age, sex, personal and family history, associated pathologies, arterial systolic and diastolic pressure, alcohol drinking habits referring to current and past consumption, cigarette consumption and pharmacological treatments. Anthropometric data included weight, height, abdominal circumference, WHR and BMI.
Methods

Patients
Laboratory assays included total cholesterol, HDLcholesterol, LDL-cholesterol, triacylglycerol, aspartate aminotransferase, alanine aminotransferase, γ-glutamyltranspeptidase, fasting serum glucose, fasting insulin and serum glucose 2 h after 75 g glucose (OGTT). For evaluation of insulin sensitivity, the HOMA of insulin resistance (HOMA-IR) test was performed [19] .
Biopsies from liver, muscle and visceral adipose tissues were obtained during bariatric surgery. Tissue samples were immediately flash-frozen in liquid nitrogen and kept at −80°C. Liver biopsies were processed conventionally for diagnostic purposes, and for histological grading and staging. Paraffinembedded sections were stained with haematoxylin and eosin. Sweet and Gordon's methods were used for reticulin, chromotrope aniline blue for connective tissue and Perl's Prussian blue for iron. Liver histology was scored according to the NAFLD histology scoring system. The severity of steatosis was graded from 0 to 3, inflammation from 0 to 3, hepatocellular ballooning from none to many, and fibrosis was staged from 0 to 4 (Table 1 ). Each liver specimen was assessed for the presence or absence of NASH by pattern recognition and for the NAFLD activity score, which is the sum of steatosis, inflammation and hepatocyte ballooning [20, 21] . Eleven patients were classified as having NASH and 15 as having simple steatosis. NASH patients were further divided into those with a NASH score of ≥3 and <5 (group 1 or less severe NASH; n=5) and those with a NASH score of ≥5 (group 2 or more severe NASH; n=6).
Immunoblotting Total protein extracts were subjected to SDS-PAGE electrophoresis [22] Immunoprecipitation of IRS-2 Total liver protein samples (1 mg) were incubated overnight at 4°C with 1 μg of IRS-2 antibody (Santa Cruz Biotechnology). Samples with antibody were added to affinity gel (EZview Red Protein G; Sigma-Aldrich, St Louis, MO, USA) and incubated overnight at 4°C. Finally, this mixture was denatured for 10 min at 95°C and phosphorylation of IRS-2 was determined by western blot analysis. The blots were incubated overnight at 4°C with a mouse monoclonal antiphosphotyrosine antibody coupled with horseradish peroxidase (Millipore, Temecula, CA, USA). IRS-2 abundance was determined in the same membrane after stripping off the immune complex for the detection of phosphotyrosine.
Caspase activity General caspase-3-, -6-, -8-and -9-like activities were evaluated by enzymatic cleavage of the chromophore p-nitroanilide from the substrates N-acetyl- -8) and N-acetyl-Leu-GluHis-Asp-p-nitroanilide (caspase-9) (Sigma-Aldrich). The proteolytic reaction was carried out using 50 μg total protein and 50 μmol/l substrate. The reaction mixtures were incubated at 37°C for 1 h and formation of p-nitroanilide was measured at 405 nm, using a 96-well plate reader.
Measurement of apoptosis TUNEL staining was performed according to the manufacturer's instructions (Serologicals, Norcross, GA, USA). Specimens were examined using a bright-field Axioskop microscope (Carl Zeiss, Jena, Germany) equipped with a Leica DM2500 camera (Leica, Wetzlar, Germany). Data were expressed as the number of TUNEL-positive cells/high-power field (magnification ×400).
Densitometry and statistical analysis The relative intensities of protein bands were analysed using a densitometric analysis program (Quantity One Version 4.6; Bio-Rad Laboratories). Statistical analysis was performed using GraphPad InStat version 3.00 (GraphPad Software, San Diego, CA, USA) for the analysis of variance and Bonferroni's multiple comparison tests. Values of p<0.05 were considered significant.
Results
Clinical, anthropometric and biochemical data Among the patients fulfilling the inclusion criteria and accepting to participate in this study, 26 were selected after undisputed classification of their liver biopsies as steatosis or NASH.
This representative group was then divided into simple steatosis and NASH (groups 1 and 2), as described above (see Table 1 ). The clinical data and characteristics of patients are summarised in Table 2 . It is important to acknowledge that simple steatosis and NASH exhibit age and sex-related differences in prevalence and severity. In this regard, patients had a similar age and BMI across the whole NAFLD spectrum, although women were not equally represented. Patients with NASH had much higher total cholesterol, LDL-cholesterol and triacylglycerol levels than those with simple steatosis (p< 0.05). Patients with less severe NASH had total cholesterol, LDLcholesterol and triacylglycerol values between those of simple steatosis and more severe NASH. HDL-cholesterol levels were significantly lower in patients with NASH than in those with simple steatosis (p<0.05). Fasting glucose and 2 h OGTT glucose levels were significantly increased in patients with more severe NASH compared with those with simple steatosis and less severe NASH (p< 0.05), possibly indicating lower glucose tolerance and higher insulin resistance in these patients. In fact, this was also supported by the HOMA-IR test, which showed a progressive increase from simple steatosis through to less severe and more severe NASH (p<0.01), thus suggesting that higher insulin resistance might correlate with more severe NAFLD stages.
Caspase-2, caspase-3 and apoptosis increase in the liver of patients with NASH Hepatocyte apoptosis is a key feature of NASH and may correlate with NAFLD severity [23, 24] .
In the present study, we showed that active caspase-2 was 2.9-and 3.5-fold increased in more severe NASH compared with less severe NASH and steatosis, respectively (p<0.01) (Fig. 1a) . Similarly, executioner active caspase-3 was increased by 3.4-fold in more severe NASH (p<0.01) (Fig. 1b) . Caspase-3-like activity assays further demonstrated increasing activity from simple steatosis to more severe NASH (p<0.05) (Fig. 1c) . Other caspases, such as caspase-6, -8 and -9, were not significantly altered between groups (data not shown), further underlying the likely significance of elevated active caspase-3 and, particularly, of active caspase-2 during NAFLD. Finally, end-stage apoptosis was evaluated using the TUNEL assay in liver tissue sections. In accordance with the previous results, the number of TUNEL-positive cells (mean±SEM) increased from 0.5±0.2 positive cells per high-power field in simple steatosis to 0.7±0.3 in less severe NASH and to 1.6±0.3 in more severe NASH (p<0.01) (Fig. 1d-g ). These results underline the significance of apoptosis in NASH and further suggest the participation of apoptosis in advancing NASH to more severe stages. In particular, caspase-2 activation might function as an important component of NAFLD.
INSR and IRS phosphorylation are strongly impaired in the muscle and liver of patients with NASH It is well established that the insulin signalling pathway is impaired in obese patients as a result of decreased INSR and IRS phosphorylation [25] . However, the degree of insulin resistance in insulin target tissues in different NAFLD stages is largely unknown. In the muscle, total INSR levels were decreased in patients with NASH. More importantly, INSR phosphorylation was decreased by 2.8-fold in more severe NASH, compared with simple steatosis (p<0.01) (Fig. 2a) . In the liver, total INSR abundance was similarly reduced, while INSR phosphorylation was~1.4-and twofold lower in less severe and more severe NASH, respectively, than in simple steatosis (p<0.05 for more severe NASH) (Fig. 2b) . In adipose tissue, INSR levels were reduced in patients with NASH, but INSR tyrosine phosphorylation did not significantly change between NAFLD disease stages (Fig. 2c) . As for IRS-1 tyrosine phosphorylation, it was found to be decreased in the muscle by almost twofold in less severe NASH (p<0.05) and by almost 15-fold in more severe NASH (p<0.01), compared with simple steatosis (Fig. 3a) . While IRS-1 is the major substrate leading to stimulation of glucose transport in muscle and adipose tissues, IRS-2 is the main mediator of insulin signalling in the liver. In these samples, IRS-2 tyrosine phosphorylation, as determined by immunoprecipitation, was similarly decreased in patients with severe NASH (p<0.05), although to a lesser extent than IRS-1 phosphorylation in the muscle (Fig. 3b) . In adipose tissue, IRS-1 tyrosine phosphorylation remained relatively unchanged (Fig. 3c) . Together, these results indicate that insulin resistance becomes more pronounced in muscle than in liver of morbidly obese patients, and less evident in adipose tissue in more severe stages of the disease, thus suggesting a correlation between insulin resistance and different stages of NAFLD.
Akt phosphorylation decreases in muscle, liver and adipose tissue of patients with NASH We next investigated whether the apparent increase of insulin resistance, from simple steatosis to more severe NASH, was also evident at the Akt level. In muscle, Akt phosphorylation decreased in NASH by almost twofold, compared with simple steatosis (p<0.01) (Fig. 4a) . Similarly, total Akt was significantly decreased among groups. The same trend in Akt phosphorylation was observed in the liver, although in a less pronounced manner (p<0.05 for more severe NASH) (Fig. 4b) , corroborating previous results [26, 27] . Surprisingly, in adipose tissue, Akt phosphorylation was also significantly impaired by around threefold in NASH patients, compared with simple steatosis (p < 0.01) (Fig. 4c) . While some authors have shown that insulin- ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GT, γ-glutamyltranspeptidase stimulated Akt phosphorylation is reduced in different tissues of obese patients, including in skeletal muscle, others have failed to detect alterations in insulin-induced Akt activation in skeletal muscle of overweight type 2 diabetic patients or even in obese participants with or without type 2 diabetes [28] . Our results corroborate the first suggestion, showing that in morbidly obese patients with NAFLD, Akt phosphorylation decreases in muscle, liver and adipose tissues in more severe stages of the disease.
JNK phosphorylation is associated with insulin resistance and apoptosis in patients with NASH JNK1 may directly induce insulin resistance [29] . In addition, some studies have demonstrated a link between JNK activation, caspase-2 and/or caspase-3 activation, and apoptosis [30, 31] , while NEFA have been shown to activate hepatocyte apoptosis in a JNK-dependent manner [32] .
Therefore, we tested the hypothesis that phosphorylated total JNK is a crucial mediator between metabolic stress and insulin resistance and apoptosis in insulin target tissues of NAFLD patients at different disease stages. Total JNK decreased from steatosis to NASH in muscle and adipose tissues, but not in the liver (Fig. 5 ). More importantly, JNK phosphorylation was significantly increased in NASH patients, compared with simple steatosis, both in muscle (p<0.01) and in liver (p<0.05) (Fig. 5a, b) . Although not significant, a similar trend was found in adipose tissue (Fig. 5c) . Thus, increased JNK phosphorylation may explain the increased insulin resistance and apoptosis in NASH, compared with simple steatosis.
Discussion
The complex mechanisms leading to the development of steatosis and its progression to different degrees of NASH are largely unknown. In addition, human studies exploring changes in liver and peripheral tissues in signalling pathways involved in cell death and insulin resistance remain scant. In this study, we investigated apoptosis in liver tissue and insulin signalling in insulin target tissues of patients with different NAFLD stages. Our results show that insulin resistance is differentially sensed in muscle, liver and adipose tissues, and that apoptosis and insulin resistance increase with more severe NAFLD stages in morbidly obese patients.
This study included severely obese patients who were undergoing bariatric surgery and typically had very mild liver involvement, with either isolated steatosis or mild NASH. Thus, the results may not be generalisable to typical obese NASH patients with moderate to severe disease. Another limitation of this study is the lack, mostly due to ethical issues, of a real control group, with normal liver, muscle and visceral fat histology. However, although important, such a control group is not crucial when comparing apoptosis and insulin signalling proteins among patients with different stages of NAFLD, which was a major goal of our study.
NAFLD and insulin resistance have been associated with occurrence of hepatocyte apoptosis [4, 33, 34] . In particular, our group has previously shown that caspase-3 and (c) adipose tissue. Liver and adipose tissue protein blots were normalised to endogenous β-actin, while muscle tissue protein blots were normalised to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Results are expressed as mean±SEM (arbitrary units); *p <0.05 and **p<0.01 for difference from steatosis activation and apoptosis are present in the liver of nonobese NASH patients [5, 19] . Our current results confirm the same in morbidly obese patients. In contrast, little is known about caspase-2 physiological functions, which may include regulation of apoptosis, cell cycle and tumour formation [35] , and virtually no information is available on the role of caspase-2 in the liver. Here, we show that caspase-2 activation increases in the liver from simple steatosis to NASH. Interestingly, caspase-2-deficient mice display reduced body fat content, when compared with agematched wild-type mice [36] , while diet-induced obese rats on dietary L-arginine supplementation gain much less white fat, concomitantly with reduced mRNA levels of caspase-2 [37] . In turn, TNF-α was shown to activate caspase-2, but not caspases-3 and -8, and also to induce apoptosis in HepG2 cells [38] , while human pancreatic beta cell death induced by saturated fatty acids was also related to increased caspase-2 activity but not to caspase-3 [39] . It is likely that caspase-2 activation affects the metabolic syndrome and apoptosis during NAFLD. The question of whether caspase-2 activation results from increased accumulation of liver fat and/or represents an active apoptosis mechanism during NAFLD or, instead, is a secondary event remains to be answered.
In this study, we report a maximum decrease in tyrosine phosphorylation of INSR and IRS-1 at the muscle level, correlating with more severe NAFLD stages. While this is consistent with the notion that insulin resistance in skeletal muscle manifests long before hyperglycaemia becomes evident [40] , it also supports the idea that fat deposition in the muscle might be a conditioning factor for the appearance and progression of NAFLD, and particularly of NASH. Importantly, a blockage in the insulin signalling cascade at the IRS-1 level is thought to be the primary defect leading to insulin resistance in the muscle. This also appears to be the case for NAFLD progression, as IRS-1 tyrosine phosphorylation was almost 15-fold downregulated in patients with more severe NASH, compared with those with simple steatosis. The mechanism by which obesity induces insulin resistance in skeletal muscle is likely to be related to the accumulation of intramyocellular fat and fatty acid metabolites [17] . Still, the cause of deposition of intramyocellular fat and its metabolites has yet to be defined.
The less evident decrease of INSR and IRS-2 activation in the liver compared with the muscle during NAFLD progression may indicate that insulin resistance in the liver is on a lag phase. Activation of Akt appears to corroborate these results in muscle and liver tissues.
Interestingly, INSR and IRS-1 activation in adipose tissue remained unchanged with NAFLD progression. Although adipose tissue is an important site of insulin resistance in NAFLD [41] and visceral fat is strongly associated with hepatic and muscular insulin resistance [42] , it appears that NAFLD progression is not dependent on, or a consequence of adipose tissue insulin resistance. Still, Akt activation was also significantly impaired in visceral fat in more advanced phases of NAFLD, namely in NASH, probably independently of a blockage at the IRS-1 level. Alternatively, phosphorylation of IRS-1 at different residues may still be occurring, thus impairing insulin signalling [43] .
JNK activation has been previously shown in human NASH [6] . In addition, JNK appears to play a crucial role in inducing insulin resistance and/or steatohepatitis in rodents [30, 44] . However, its phosphorylation state in other insulin target tissues or in different stages of NAFLD has never been evaluated before. This is particularly relevant, as obesity is known to cause broad chronic lowgrade inflammatory responses that lead to activation of stress pathways, in particular of JNK. Our findings show that in muscle tissue, total JNK phosphorylation was significantly increased in NASH patients, compared with simple steatosis. In the liver, this increase was more moderate and in visceral fat it was absent. These results suggest that in human participants with morbid obesity, JNK phosphorylation may be responsible for aggravating insulin resistance as NAFLD advances to more severe forms. Interestingly, JNK activation may also induce apoptosis, thus providing a link between insulin resistance and cell death in different NAFLD stages [45] . In fact, a connection between liver JNK, caspase-2 and apoptosis is an attractive hypothesis, as it was recently shown that caspase-2-and JNK-mediated signalling is one of the mechanisms involved in age-related muscle cell apoptosis [46] . Curiously, our team very recently demonstrated that caspase-2 is a specific key downstream target of JNK in amyloid β-induced apoptosis [47] . However, the role of different JNK isoforms in different human insulin target tissues remains to be explored. In fact, this might constitute a road block to a possible therapeutic approach involving JNK inhibition, as hepatic JNK1 in mice appears to inhibit liver steatosis in contrast to adipose tissue JNK1 [16] . In addition, JNK2 appears to inhibit hepatocyte cell death by blocking the mitochondrial pathway of apoptosis in mice fed a high-fat diet [44] .
In conclusion, this study clarifies the involvement of apoptosis, caspase-2 and insulin resistance in different NAFLD stages and in different insulin target tissues. In particular, more severe cases of NAFLD are associated with increased caspase-2 and -3 activation, as well as apoptosis in the liver. In addition, insulin resistance may primarily target the muscle tissue as NAFLD advances to more severe stages, although the liver tissue is also affected. Finally, JNK is suggested as a mechanistic link between insulin resistance and apoptosis during NAFLD progression and may represent an attractive pharmacological target for the development of drugs for the treatment of insulin resistance-associated NAFLD.
